Sigilon Therapeutics Third Quarter 2022 Earnings: Beats Expectations
Sigilon Therapeutics (NASDAQ:SGTX) Third Quarter 2022 Results
Key Financial Results
Revenue: US$4.25m (up 118% from 3Q 2021).
Net loss: US$8.67m (loss narrowed by 57% from 3Q 2021).
US$0.27 loss per share (improved from US$0.63 loss in 3Q 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Sigilon Therapeutics Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 70%. Earnings per share (EPS) also surpassed analyst estimates by 36%.
Looking ahead, revenue is expected to decline by 3.9% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 14%.
Performance of the American Biotechs industry.
The company's shares are down 4.8% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 4 warning signs for Sigilon Therapeutics you should be aware of, and 1 of them is significant.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
